A joint consensus from KDIGO and ADA recommends SGLT-2 inhibitors with proven kidney benefits for patients with T2D, CKD, and an eGFR greater than 20 mL/min/1.73 m2 [87]. Here, SLC5A2 is linked to type 2 diabetes mellitus.